Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience

• Published in: AIDS (London) Vol. 33; no. 11; pp. F13 - F19
• Main Authors: Spano, Jean-Philippe, Veyri, Marianne, Gobert, Aurélien, Guihot, Amélie, Perré, Philippe, Kerjouan, Mallorie, Brosseau, Solenn, Cloarec, Nicolas, Montaudié, Henri, Helissey, Carole, Flament, Thomas, Gounant, Valérie, Lavolé, Armelle, Poizot-Martin, Isabelle, Katlama, Christine
• Format: Journal Article
• Language: English
• Published: England Copyright Wolters Kluwer Health, Inc 01.09.2019; Wolters Kluwer
• Subjects: Life Sciences; Santé publique et épidémiologie; cancer; HIV; safety; efficacy; immunotherapy
• ISSN: 0269-9370; 1473-5571
• DOI: 10.1097/QAD.0000000000002298

OBJECTIVE:To report efficacy and tolerance of nivolumab or pembrolizumab, PD-1 inhibitors, in people living with HIV (PLWHIV) and cancer. DESIGN:Series of PLWHIV cancer patients treated with anti-PD1 agents in real-life clinical practice. METHODS:From May 2014 to January 2019, 575 HIV-infected patients have been discussed in the French CANCERVIH national multidisciplinary board and included in the network database. Twenty-three patients were treated with immune checkpoint inhibitors in daily practice. We report the demographic characteristics, CD4 T-cell counts, HIV viral loads, safety and efficacy data of these 23 PLWHIV treated in routine practice with nivolumab or pembrolizumab for nonsmall cell lung cancer (n = 21), melanoma (n = 1) and head and neck cancer (n = 1) retrospectively collected from the database CANCERVIH network. The median CD4 T-cell count at treatment initiation was 370 cells/μl (IQR125–1485). HIV viral load was undetectable in all patients. RESULTS:As of 29 April 2019, with a median follow-up of 10.8 months (2.0–27.7), the median number of injections was 6 (IQR4–18). Only two grade 3 adverse reactions were reported (no toxic deaths or immune-related deaths). Among the 23 patients, a partial response was observed in five patients (22%), a stabilization for five (22%) and a progression in 13 (57%). Only one patient experienced a positive HIV viral load, but this occurred following ART interruption. CONCLUSION:Treatment with PD-1 inhibitors seems to have an efficacy signal and be well tolerated in PLWHIV, including impact on CD4 lymphocyte count and HIV load, that should be monitored during treatment course (regarding real-life experience).